Skip to main content
. Author manuscript; available in PMC: 2010 Aug 15.
Published in final edited form as: Biochem Pharmacol. 2009 May 3;78(4):355–364. doi: 10.1016/j.bcp.2009.04.023

Figure 1.

Figure 1

The structure of FG020326 (A); Reversal of MDR in vivo by FG020326 (B and C), the experiment was carried out using athymic mice implanted subcutaneously (s.c.) with KBv200 cells. The treatments were administered as indicated in the “Materials and Methods”. Data represent the mean tumor volume for each group ± SD in 10 mice after implantation; The pharmacokinetic study of FG020326 (D), HPLC analysis was performed as described in the “Material and Methods”. The data represent the means and standard deviations of three independent experiments.